KNSA vs NVS
KNSA: Kiniksa is a biopharmaceutical company developing and commercializing therapies for chronic inflammatory and autoimmune diseases, with a pipeline featuring novel treatments for recurrent pericarditis. NVS: Novartis is a leading global pharmaceutical company focused on discovering and developing innovative, high-efficacy medicines across oncology, immunology, and neuroscience.
Side-by-side fundamentals
| Metric | KNSA | NVS | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $83.17 | $153.64 | |
| Market cap | $6.5B | $286.6B | |
| P/E as of 2026-10-20 | 91.40 | n/a | |
| Net margin FY2025, SEC XBRL | +8.7% | n/a | |
| Operating margin FY2025, SEC XBRL | +11.4% | n/a | |
| ROE FY2025, SEC XBRL | +10.4% | +30.0% | NVS higher |
| ROA FY2025, SEC XBRL | +7.7% | +12.6% | NVS higher |
| Revenue growth (YoY) FY2025, SEC XBRL | +60.1% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +45.5% | n/a | |
| Dividend yield as of 2026-09-03 | n/a | +3.4% | |
| Dividend streak (yrs) SEC XBRL | 0 | n/a | |
| Beta as of 2026-09-02 | 0.44 | 0.22 | |
| 1-year return as of 2026-10-20 close | +113.3% | +16.6% | KNSA higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.